1. Metabolic Enzyme/Protease
  2. Thrombin

NQ301 

Cat. No.: HY-101054 Purity: 98.74%
Data Sheet SDS Handling Instructions

NQ301 is an antithrombotic agent; inhibits collagen-challenged rabbit platelet aggregation with an IC50 of 10 mg/mL.

For research use only. We do not sell to patients.
NQ301 Chemical Structure

NQ301 Chemical Structure

CAS No. : 130089-98-4

Size Price Stock Quantity
10 mM * 1 mL in DMSO $61 In-stock
5 mg $55 In-stock
10 mg $90 In-stock
25 mg $190 In-stock
50 mg $250 In-stock
100 mg $450 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Featured Recommendations

Related Screening Libraries:

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

NQ301 is an antithrombotic agent; inhibits collagen-challenged rabbit platelet aggregation with an IC50 of 10 mg/mL.

IC50 & Target

IC50: 0.60±0.02 μM (collagen-challenged rabbit platelet aggregation), 0.58±0.04 μM (U46619-challenged rabbit platelet aggregation), 0.78±0.04 μM (arachidonic acid-challenged rabbit platelet aggregation)[1]

In Vitro

NQ301 concentration-dependently inhibits collagen (10 mg/mL)-, U46619 (1 mg/mL)- and arachidonic acid (100 mg/mL)-challenged rabbit platelet aggregation, with IC50 values of 0.60±0.02, 0.58±0.04 and 0.78±0.04 μM, respectively. NQ301 potently suppresses thromboxane B2 formation by platelets that are exposed to arachidonic acid in a concentration-dependent manner, but had no effect on the production of prostaglandin D2, indicating an inhibitory effect on thromboxane A2 synthase. NQ301 has a potential to inhibit thromboxane A2 synthase activity with thromboxane A2/prostaglandin H2 receptor blockade, and modulate arachidonic acid liberation as well as 12-hydroxy-5,8,10,14-eicosatetraenoic acid formation in platelets[1]. NQ301 inhibits platelet aggregation by suppression of the intracellular pathway, rather than by direct inhibition of fibrinogen-GPIIb/IIIa complex binding. NQ301 significantly inhibits the increase of cytosolic Ca2+ concentration and ATP secretion, and also significantly increases platelet cAMP levels in the activated platelets. The antiplatelet activity of NQ301 may be mediated by inhibition of cytosolic Ca2+ mobilization, enhancement of cAMP production and inhibition of ATP secretion in activated platelets[2].

References
Preparing Stock Solutions
Concentration Volume Mass 1 mg 5 mg 10 mg
1 mM 3.0698 mL 15.3492 mL 30.6984 mL
5 mM 0.6140 mL 3.0698 mL 6.1397 mL
10 mM 0.3070 mL 1.5349 mL 3.0698 mL
Please refer to the solubility information to select the appropriate solvent.
Cell Assay
[1]

ished rabbit platelet suspension is challenged by addition of collagen (10 mg/mL), arachidonic acid (100 μM) or U46619 (1 μM). Concentration- response relationship is determined in the absence or presence of a range of concentrations of NQ301 (0, 0.25, 0.5, 0.75, 1 μM); aspirin-treated platelets (50 μM for 5 min) are used to prevent any possible contribution of endogenous arachidonic acid metabolites to platelet aggregation. The resulting aggregation, measured as the change in light transmission, is recorded for 5 min. The extent of platelet aggregation is expressed as % of the control[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References
Molecular Weight

325.75

Formula

C₁₈H₁₂ClNO₃

CAS No.

130089-98-4

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: ≥ 29 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number *

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
NQ301
Cat. No.:
HY-101054
Quantity: